Chemotherapy-Induced Peripheral Neuropathy Impacts Quality Of Life And Activities Of Daily Living Of Brazilian Multiple Myeloma Patients
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Survival in multiple myeloma (MM) has improved in the past years with the introduction of immunomodulators and proteasome inhibitors. However, chemotherapy-induced peripheral neuropathy (CIPN) is associated with both drug classes affecting Health-Related Quality of Life (HRQoL) and activities of daily living (ADL).
OBJECTIVE: We evaluated CIPN in MM patients to identify associated factors and impacts on HRQoL and ADL.
METHODS: This is a cross-sectional study with Brazilian patients from public and private health services. Patients were interviewed using validated tools to measure CIPN and HRQoL, along with sociodemographic and clinical questions. Logistic regression was used to assess the association of CIPN with sociodemographic, clinical, and HRQoL variables.
RESULTS: In total, 217 patients were eligible for the study. The median age was 67, 50.9% were women, 51.6% had low income, 47.5% had low education, and 55.3% attended private health services. The chemotherapy regimen most used was the combination of cyclophosphamide, thalidomide, and dexamethasone (17.5%) among the 24 types of regimens found. Most patients (90.3%) had at least one CIPN symptom: 62.7% were severe, and 51.62% were extremely bothered ADL. Numbness was the most common symptom (40.6%). CIPN was independently associated with education, hospitalization, chemotherapy, side effects, disease symptoms, and global health status in HRQoL.
CONCLUSION: MM patients showed a high frequency of CIPN, which affected ADL and impaired HRQoL. Early and accurate detection of CIPN and dose management in patients with thalidomide and bortezomib-based regimens should be performed to provide better treatment outcomes and avoid permanent disabilities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Current drug safety - (2023) vom: 17. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Miranda Drummond, Paula Lana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bortezomib |
|---|
| Anmerkungen: |
Date Revised 18.08.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1574886318666230817162424 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360916260 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360916260 | ||
| 003 | DE-627 | ||
| 005 | 20231226084032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1574886318666230817162424 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360916260 | ||
| 035 | |a (NLM)37592770 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Miranda Drummond, Paula Lana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chemotherapy-Induced Peripheral Neuropathy Impacts Quality Of Life And Activities Of Daily Living Of Brazilian Multiple Myeloma Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Survival in multiple myeloma (MM) has improved in the past years with the introduction of immunomodulators and proteasome inhibitors. However, chemotherapy-induced peripheral neuropathy (CIPN) is associated with both drug classes affecting Health-Related Quality of Life (HRQoL) and activities of daily living (ADL) | ||
| 520 | |a OBJECTIVE: We evaluated CIPN in MM patients to identify associated factors and impacts on HRQoL and ADL | ||
| 520 | |a METHODS: This is a cross-sectional study with Brazilian patients from public and private health services. Patients were interviewed using validated tools to measure CIPN and HRQoL, along with sociodemographic and clinical questions. Logistic regression was used to assess the association of CIPN with sociodemographic, clinical, and HRQoL variables | ||
| 520 | |a RESULTS: In total, 217 patients were eligible for the study. The median age was 67, 50.9% were women, 51.6% had low income, 47.5% had low education, and 55.3% attended private health services. The chemotherapy regimen most used was the combination of cyclophosphamide, thalidomide, and dexamethasone (17.5%) among the 24 types of regimens found. Most patients (90.3%) had at least one CIPN symptom: 62.7% were severe, and 51.62% were extremely bothered ADL. Numbness was the most common symptom (40.6%). CIPN was independently associated with education, hospitalization, chemotherapy, side effects, disease symptoms, and global health status in HRQoL | ||
| 520 | |a CONCLUSION: MM patients showed a high frequency of CIPN, which affected ADL and impaired HRQoL. Early and accurate detection of CIPN and dose management in patients with thalidomide and bortezomib-based regimens should be performed to provide better treatment outcomes and avoid permanent disabilities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Peripheral neuropathy | |
| 650 | 4 | |a bortezomib | |
| 650 | 4 | |a drug safety | |
| 650 | 4 | |a health-related quality of life | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a thalidomide | |
| 700 | 1 | |a Dos Santos, Roberta Márcia Marques |e verfasserin |4 aut | |
| 700 | 1 | |a Silveira, Lívia Pena |e verfasserin |4 aut | |
| 700 | 1 | |a Malta, Jéssica Soares |e verfasserin |4 aut | |
| 700 | 1 | |a Reis, Adriano Max Moreira |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Naiane Lima |e verfasserin |4 aut | |
| 700 | 1 | |a de Paula E Silva, Roberta Oliveira |e verfasserin |4 aut | |
| 700 | 1 | |a Fagundes, Evandro Maranhão |e verfasserin |4 aut | |
| 700 | 1 | |a de Pádua, Cristiane Aparecida Menezes |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g (2023) vom: 17. Aug. |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:17 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574886318666230817162424 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 17 |c 08 | ||